Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Easton Provides Update on the Closing of its Agreement To Acquire Commercial Bakery with Projected Revenues Over $20,000,000 per Year and Positioned to Enter the Cannabis Edibles MarketPress Release | 04/08/2019
TORONTO, ON / ACCESSWIRE / April 8, 2019 / Easton Pharmaceuticals Inc. (OTC PINK: EAPH) provides update on the closing of its agreement to acquire a commercial bakery with existing revenues and projected to reach over $20,000,000 within 12 months.
Easton announced earlier in March that it had signed a Definitive Agreement to acquire a commercial bakery and food preparation company with existing revenues and projected revenues in excess of $20,000,000 over the next 12 months. Easton's legal counsel believes that all documents will be completed this week with signatures and exchange of documents.
Easton is acquiring a revenue generating commercial bakery and food preparation company in Toronto, Ontario, Canada. The bakery operates from a 40,000 square foot production facility and produces white label food products for third party food companies and its own line of niche food product lines, sold in major grocery chains, as well as specialty coffee chains in Canada and the United States. The company has an R&D division with full product development.
The Company recently announced that it has also signed a Letter of Intent with a Licensed Producer of medical marijuana in Canada in order to develop and supply cannabis edible products through its client network. Easton has had several meetings with the principals of the LP and is working towards completing a Definitive Agreement.
Easton has been working on a transition plan in anticipation of the closing and has been involved in the daily operations of the business since the Definitive Agreement was signed. More information will be announced and disclosed once the transaction is completed.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing medical drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton, together with BMV Medica S.A. own the exclusive distribution rights in Mexico and Latin America for two patented women's diagnostic products and a novel natural treatment for Bacterial Vaginosis, which they have sub-licensed to Bayer and Gedeon Richter. In addition, a generic cancer drugs line is being developed for sale in Mexico. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs. As part of its strategic growth plan, the Company has entered new lucrative market segments globally, including Gaming, Real Estate Development, Food and Beverage and Cannabis and has already created divisions.
For More Information on Easton and Affiliated and Partner Company's Visit:
http://www.eastonpharmaceuticalsinc.com ;
http://finance.yahoo.com/q?s=eaph ;
https://twitter.com/eastonpharma
Thank you Pistole!
Would be nice to see products and PRs of this company is doing anything and to seal the deal financial's to back those PR. I think this will be very very stable
No proof of an RS coming. Qban purposely being held down. Only a matter of time before this puppy pops
Only time my friend. So far very stable in this area. Been super busy with projects at work. Im still holding and waiting. Thats all we need.
I just read this and I understand. Ive been trading for 10 years. The stock market always changes and companies we least expect rise. This stock has the ability to move but bashing wont help. I can only post on news and financials and chart stats. I only post of the PRs match the financial releases. Its the safest bet. Once again very sorry for you loss but weve all been there at one point. We'll at least I have. Just keep moving investing and making money my friend.
Sorry been super busy at work. Be back here on Monday. EAPH is still good to go
Easton Announces Signing of Joint Venture Agreement for the Purchase and Development of 9 Townhomes with Revenue in Excess of $4 Million and Provides Update on its Framing Contract with Revenues of $770K for Q1
TORONTO, ON / ACCESSWIRE / April 2, 2019 / Easton Pharmaceuticals Inc. (OTC PINK: EAPH) Announces that is has signed a Joint Venture Agreement for the purchase and development of 9 townhomes in Welland, Ontario and provides update on its ongoing contract for the framing of 150 homes in Whitby, Ontario.
Easton is pleased to have signed a joint venture agreement for the purchase and development of 9 townhomes in Welland, Ontario, which is less than 30 minutes from Niagara Falls, Canada. The project will generate in excess of $4 million in revenues over the next 12 months and is scheduled to commence in the next 60 days, once all permits have been issued. This will be the second development project the Company has commenced, after its acquisition of approximately 3 acres in Cobourg, Ontario, where Easton is converting an existing heritage mansion into 6 luxurious residential condominium units, that will generate $2 million in profit for the Company and is expected to generate over $30 million over 3 years with the development of approximately 42 residential units.
Easton has achieved consistent revenues through its various operations and is growing its business daily. The Company has generated over $770,000 in the first quarter of 2019 from its framing contract alone, which it entered into in the last quarter of 2018 for the framing of 150 homes in Whitby, Ontario with a prominent local builder.
Easton further expects the launch of its women's health care products in Mexico in Q2 by multi-national Bayer, whereby Bayer will be making royalty payments to Easton and BMV, Easton's JV partner.
The Company also owns an interest in 135 acres in Georgina, Ontario and is working on a new plan for that property, which was appraised at over $8 million.
Easton has been seeing continued increase in its revenues from its various business initiatives and is committed to continuing to grow the business and realize extraordinary returns for the benefit of its shareholders and investors.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing medical drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton, together with BMV Medica S.A. own the exclusive distribution rights in Mexico and Latin America for two patented women's diagnostic products and a novel natural treatment for Bacterial Vaginosis, which they have sub-licensed to Bayer and Gedeon Richter. In addition, a generic cancer drugs line is being developed for sale in Mexico. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs. As part of its strategic growth plan, the Company has entered new lucrative market segments globally, including Gaming, Real Estate and Development, Food and Beverage and Cannabis.
For More Information on Easton Visit:
http://www.eastonpharmaceuticalsinc.com ;
http://finance.yahoo.com/q?s=eaph ;
https://twitter.com/eastonpharma
Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.
CONTACT INFORMATION
Easton Pharmaceuticals, Inc.
Tel: 647-362-5700
Email: eastonpharma@protonmail.com
SOURCE: Easton Pharmaceuticals, Inc.
© Copyright 2019 ACCESSWIRE. All Righ
Seeing some great positivity on the board. Great turnaround stock. Huge pop coming soon
All in the fins. Shows everything. No retractions no dilution revs about a milliom on 6 month. Looks good
False. Movement and chart stats are good
Definitely not true. Fins are correct and matches PRs.
Thanks! This just needs volume. A good press release addressing shareholders will be great so far nice churn and expecting a move up soon.
Wrong again. EAPH has been moving from .01 to .025 for months. The price is low and the stock trading and pps is undervalued with the recent filings and news
Nice close today. Selling dried up, RSI's at perfect levels, level 2s thin, bid gap being filled and chart showing a nice stable up trend. Rising on the breakout boards and more people seeing EAPH.
All companies have to pay to release a press release. PR - Press Relese = company must be paid to publish it. Thats how press releases get released.
Thank you Pistole!!
Moving up the breakout boards nicely. More eyes on EAPH. This puppy is gearing up for a breakout
There are NO dilutive MM's on the bid or ask. Therefore there is no dilution. Also, there are only retail MMs on the bid and ask. If there was dilution (which cant be proven) then its over.
As of right now the price is churning withing the .01 range building a nice base.
EAPH - Squeeze coming. Level 2s very thin.
378k in revs for 2018 and 770k in revenues for 2019 1st QTR.
If that were the case then trading 101 would be in play. Ask would be higher than the bid and percentages would be in the negative. Level 2s would show MMs with many shares and trade volume wouldnt be low with a positive percentage.
$EAPH - Easton Announces Signing of Joint Venture Agreement for the Purchase and Development of 9 Townhomes with Revenue in Excess of $4 Million and Provides Update on its Framing Contract with Revenues of $770K for Q1
Tuesday, April 2, 2019 9:00 AM
TORONTO, ON / ACCESSWIRE / April 2, 2019 / Easton Pharmaceuticals Inc. (OTC PINK: EAPH) Announces that is has signed a Joint Venture Agreement for the purchase and development of 9 townhomes in Welland, Ontario and provides update on its ongoing contract for the framing of 150 homes in Whitby, Ontario.
Easton is pleased to have signed a joint venture agreement for the purchase and development of 9 townhomes in Welland, Ontario, which is less than 30 minutes from Niagara Falls, Canada. The project will generate in excess of $4 million in revenues over the next 12 months and is scheduled to commence in the next 60 days, once all permits have been issued. This will be the second development project the Company has commenced, after its acquisition of approximately 3 acres in Cobourg, Ontario, where Easton is converting an existing heritage mansion into 6 luxurious residential condominium units, that will generate $2 million in profit for the Company and is expected to generate over $30 million over 3 years with the development of approximately 42 residential units.
Easton has achieved consistent revenues through its various operations and is growing its business daily. The Company has generated over $770,000 in the first quarter of 2019 from its framing contract alone, which it entered into in the last quarter of 2018 for the framing of 150 homes in Whitby, Ontario with a prominent local builder.
Easton further expects the launch of its women's health care products in Mexico in Q2 by multi-national Bayer, whereby Bayer will be making royalty payments to Easton and BMV, Easton's JV partner.
The Company also owns an interest in 135 acres in Georgina, Ontario and is working on a new plan for that property, which was appraised at over $8 million.
Easton has been seeing continued increase in its revenues from its various business initiatives and is committed to continuing to grow the business and realize extraordinary returns for the benefit of its shareholders and investors.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing medical drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton, together with BMV Medica S.A. own the exclusive distribution rights in Mexico and Latin America for two patented women's diagnostic products and a novel natural treatment for Bacterial Vaginosis, which they have sub-licensed to Bayer and Gedeon Richter. In addition, a generic cancer drugs line is being developed for sale in Mexico. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs. As part of its strategic growth plan, the Company has entered new lucrative market segments globally, including Gaming, Real Estate and Development, Food and Beverage and Cannabis.
For More Information on Easton Visit:
http://www.eastonpharmaceuticalsinc.com ;
http://finance.yahoo.com/q?s=eaph ;
https://twitter.com/eastonpharma
Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.
CONTACT INFORMATION
Easton Pharmaceuticals, Inc.
Tel: 647-362-5700
Email: eastonpharma@protonmail.com
SOURCE: Easton Pharmaceuticals, Inc.
See that bid support. Early sign of a move up.
I know this stock can hit at least .10 we just need otc markets updated. Thats it. Once DBMM becomes tradable theres no stopping it
Easton Announces Filing of Its Financial Statements for the Year Ended December 31, 2018 with a Revenue Increase of 145% Over 2017 and Provides General Business UpdatePress Release | 03/18/2019
TORONTO, ON / ACCESSWIRE / March 18, 2019 / Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) Announces that it has filed its Financial Statements for the Year Ended December 31, 2018 and provides general updates on Its business initiatives.
Easton realized revenues of $378,589 USD during 2018, an increase in revenues over 145% from 2017. The Company's revenues primarily derived during the last 2 quarters from activities generated from its Georgina property, as well as from its construction contract to frame 150 new homes, through its Real Estate and Development Division. Easton's management announced last year that it would be entering into additional lucrative market segments that its directors have experience in.
The Company has created a Real Estate and Development Division, which will manage its ownership in its Georgina property, as well as its recently acquired Cobourg development property. This Division also provides construction services to builders and other clients, such as its framing contract. Easton has also created a Gaming Division, a Food and Beverage Division and a Cannabis Division. The Company is maintaining its Pharmaceutical Division, which includes a lucrative distribution agreement with BAYER, scheduled to launch in Q2. Additional consumer products are currently being negotiated and will be added to the Pharmaceutical Division. The Gaming Division is expected to complete a profitable agreement with a casino in the United States in Q2, while Easton recently announced its acquisition of a commercial bakery and food processing facility in Toronto, which is scheduled to close later this month and will mark its entry into the Food and Beverage industry. The Company's Cannabis Division is also in discussions with several Licensed Producers of Medicinal Marijuana in Canada and hopes to complete a strategic partnership shortly.
Easton has put in place the infrastructure that the Company will require to effectively and efficiently manage its operations and growth moving forward.
Thank you!
No amendements done. 1 million plus in revs for the last 6 months
Framing money pouring in 1 million in 6 months. Financials from 2018 can verify 378k as promised by EAPH!
Easton Announces Status Update On Its $2,600,000 Framing Contract To Construct 150 Homes, Including Update on Its Development Project in Cobourg, OntarioPress Release | 03/13/2019
TORONTO, ON / ACCESSWIRE / March 13, 2019 / Easton Pharmaceuticals Inc. (OTC PINK: EAPH) Provides Update on Its $2,600,000 CDN framing contract to build approximately 150 homes just outside of Toronto, Ontario, including an update on its development project to construct upto 42 new homes on an approximately 2.7 acres property it recently acquired in Cobourg, Ontario.
Easton recently announced that it has entered into a $2,600,000 CDN framing contract and has commenced work on the framing of approximately 150 homes with a well-known prominent regional builder.
Easton received approximately $275,000 CDN during its last quarter (October to December 2018) in payments from its framing contract of 150 homes and has received a further $300,000 CDN in payments for the months of January and February 2019 so far. The project is well underway and the framing contract is on schedule.
In the meanwhile, Easton has been working with its architects on the site plan for its recently acquired property in Cobourg, Ontario, which consists of a 10,000 square foot heritage mansion on approximately 2.7 acres. The development proposes the construction of up to 42 residential units in 3 phases, with the first phase approved and ready for 6 units in the existing mansion. The Company expects profits of over $2,000,000 CDN from the first phase.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing medical drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton, together with BMV Medica S.A. own the exclusive distribution rights in Mexico and Latin America for two patented women's diagnostic products and a novel natural treatment for Bacterial Vaginosis, which they have sub-licensed to Bayer and Gedeon Richter. In addition, a generic cancer drugs line is being developed for sale in Mexico. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs.
As part of its strategic growth plan, the Company has entered additional lucrative market segments and has created a Food & Beverage Division, a Construction & Development Division, a Gaming Diving and a Cannabis Division.
For More Information on Easton and Affiliated and Partner Company's Visit:
http://www.eastonpharmaceuticalsinc.com ;
http://finance.yahoo.com/q?s=eaph ;
https://twitter.com/eastonpharma
Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.
CONTACT INFORMATION
Easton Pharmaceuticals Inc.
www.eastonpharmaceuticalsinc.com
Tel: 647.362.5700
Email: eastonpharma@protonmail.com
SOURCE: Easton Pharmaceuticals Inc.
Easton Commences Cannabis Edibles Division and Announces Updates on Its Filing for the Period Ended December 31, 2018Press Release | 03/11/2019
TORONTO, ON / ACCESSWIRE / March 11, 2019 / Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces that it has commenced the set-up of a Cannabis Edibles division, pursuant to its acquisition of a commercial bakery and food production facility.
Easton has entered into discussions with several Licensed Producers in Canada to develop a line of Cannabis Edibles that can be sold through the LP's, as well as through the existing distribution channels of the commercial bakery and food processing company that Easton recently signed an agreement to acquire. Easton has been discussing the development of baked goods and other food products infused with cannabis, with several well-known retail chains. The Company has added a QA and R&D expert in the field to assist in the development of the division. Easton expects to be one of the first to enter the market to supply cannabis edibles, once it is legalized in Canada later this year.
Easton recently announced that it has signed an agreement to acquire a Toronto based commercial bakery and food preparation company which manufactures white labelled food products for third party food companies and its own line of niche food product lines, sold in major grocery chains, as well as specialty coffee chains.
In the meanwhile, Easton is pleased to announce that it will be filing its year end statements this week with OTC Markets, for the period ended December 31, 2018 with revenues derived from its framing contract of 150 homes, just outside of Toronto. That contract has been progressing well with revenues continuing.
Maybe higher ;)
770k Revs for 2019. 1 million total in the last 6 months. Waay undervalued
Annual report shows 378k revs. - 145% imcrease. Great turnaround stock.
Easton Announces Filing of Its Financial Statements for the Year Ended December 31, 2018 with a Revenue Increase of 145% Over 2017 and Provides General Business UpdatePress Release | 03/18/2019
TORONTO, ON / ACCESSWIRE / March 18, 2019 / Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) Announces that it has filed its Financial Statements for the Year Ended December 31, 2018 and provides general updates on Its business initiatives.
Easton realized revenues of $378,589 USD during 2018, an increase in revenues over 145% from 2017. The Company's revenues primarily derived during the last 2 quarters from activities generated from its Georgina property, as well as from its construction contract to frame 150 new homes, through its Real Estate and Development Division. Easton's management announced last year that it would be entering into additional lucrative market segments that its directors have experience in.
The Company has created a Real Estate and Development Division, which will manage its ownership in its Georgina property, as well as its recently acquired Cobourg development property. This Division also provides construction services to builders and other clients, such as its framing contract. Easton has also created a Gaming Division, a Food and Beverage Division and a Cannabis Division. The Company is maintaining its Pharmaceutical Division, which includes a lucrative distribution agreement with BAYER, scheduled to launch in Q2. Additional consumer products are currently being negotiated and will be added to the Pharmaceutical Division. The Gaming Division is expected to complete a profitable agreement with a casino in the United States in Q2, while Easton recently announced its acquisition of a commercial bakery and food processing facility in Toronto, which is scheduled to close later this month and will mark its entry into the Food and Beverage industry. The Company's Cannabis Division is also in discussions with several Licensed Producers of Medicinal Marijuana in Canada and hopes to complete a strategic partnership shortly.
Easton has put in place the infrastructure that the Company will require to effectively and efficiently manage its operations and growth moving forward.
# 12 on the Break out Boards!! Gooo EAPH more and more eyes on this puppy
Looking good last of .0103s are falling. Next up .0108 beautiful churn get ready for a pop in pps soon. Low volume moves this
Correction nothing until .0120
Now level 2s have nothing to .0108. Any buying now just brings it up and flippers will chase
$EAPH - Level 2s thinned out. Shortsqueeze expected. Moving nicely with perfect RSI's. 378k revs in 2018 and 2019 1st QTR 770k in revs. 1 million in the last 6 months
.0103s up almost cleared